School of Chinese Medicine signs cooperation framework agreements with Mainland pharmaceutical company
13 Jul 2015
The School of Chinese Medicine (SCM) and the Beijing Tide Pharmaceutical Company Limited (Tide) signed two cooperation framework agreements on 8 July, setting the way forward for collaborations in drug discovery and consolidation in the use of healthcare data to foster public health and wellness.
The signing of the agreements by Professor Lu Aiping, Dean of SCM, and Ms Cheng Cheung-ling, Managing Director of Tide, was witnessed by Professor Rick Wong, Acting President and Vice-Chancellor, Dr Zhang Ge, Associate Director of the Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ) and the Institute of Integrated Bioinformedicine and Translational Science (IBTS) of SCM, and Miss Theresa Tse, Executive Director and Chairman of the Board of Directors of Sino Biopharmaceutical Limited, the parent company of Tide.
Professor Rick Wong said that Tide, the first high-technology pharmaceutical company in the Chinese mainland to develop, manufacture and sell targeted drugs, shares the same mission of improving human health as SCM. He looked forward to the discovery of innovative drugs in the near future through collaborations between the two parties.
Under the agreements, TMBJ and IBTS under the School of Chinese Medicine will embark on a number of collaborations with Tide. The collaborations between TMBJ and Tide will focus on the discovery of new drugs to treat chronic inflammatory diseases, autoimmune diseases, malignant tumours, and bone and joint diseases as well as the development of new drug delivery systems. The two parties will also join hands to nurture postgraduate and postdoctoral researchers, and set up a research and development centre devoted to the creation of new models of drug discovery. In addition, IBTS will collaborate with Tide on the integration and development of healthcare data related to chronic diseases, refractory diseases and malignant tumours.